Lite Strategy, Inc. Asset Resilience Ratio
Lite Strategy, Inc. asset resilience ratio. Lite Strategy, Inc. (LITS) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Lite Strategy, Inc. (LITS) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lite Strategy, Inc. (2021–2025)
Asset resilience ratio of Lite Strategy, Inc. from 2021 to 2025. This chart shows how Lite Strategy, Inc.'s Asset Resilience Ratio has changed over time. Read total liabilities of Lite Strategy, Inc. for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lite Strategy, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Lite Strategy, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Lite Strategy, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Lite Strategy, Inc. Industry Peers by Asset Resilience Ratio
Compare Lite Strategy, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Lite Strategy, Inc. Asset Resilience Ratio by Year (2021–2025)
Lite Strategy, Inc. asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Lite Strategy, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | $0.00 | $18.29 Million | -- |
| 2024-06-30 | 83.72% | $34.64 Million | $41.38 Million | +14.37pp |
| 2023-06-30 | 69.35% | $83.79 Million | $120.81 Million | -7.97pp |
| 2022-06-30 | 77.32% | $137.51 Million | $177.84 Million | -5.90pp |
| 2021-06-30 | 83.22% | $144.88 Million | $174.10 Million | -- |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.